The Europe Viscosupplementation market segments include single dose, delayed onset of action (DAA) capsules, sustained-release capsules, and multiple-dose vial products. Based on therapeutic product type, the European market is further divided into single injection, three-dose, and five-dose capsules. Single-dose capsules are recommended to be used as an immediate relief for allergic rhinitis and may provide significant clinical improvement, while three or five-dose capsules are recommended for patients with mild to moderate chronic rhinitis and provide significant clinical improvement. For patients who have moderate to severe persistent sinusitis it is not recommended due to the slow elimination phase associated with the product and prolonged release of medications in the body.
The increasing prevalence of patients who require frequent hospital admissions and long periods of operative management can be expected to result in a dramatic increase in the Europe Viscosupplementation market over the forecast period. The growing popularity of the single-dose regime can be attributed to the ease of administration, consistent delivery system, and adequate pain relief. The single-dose capsules are usually manufactured in single batches and delivered to the patients in accordance with the manufacturing instructions. The three and five-dose capsules can be manufactured in volume quantities and are often shipped in refrigerated conditions for longer shelf life. Single-dose and three and five-dose options are currently being marketed across Europe.
Read More : https://bit.ly/3gIysOb
